期刊文献+

热激蛋白gp96免疫学功能及在主动免疫治疗肿瘤和传染病中的应用 被引量:4

Immune activity of heat shock protein gp96 and its application in active immunotherapy for tumor and infectious diseases
原文传递
导出
摘要 热激蛋白gp96可特异性结合来源于肿瘤和病毒的抗原肽,与抗原呈递细胞表面CD91等受体作用进入胞内,并在内质网中将结合的抗原通过抗原呈递链呈递给MHCI类分子,激活特异性T细胞。同时,与细胞表面Toll样受体(TLR)TLR2、TLR4等相互作用,激活天然免疫。近期研究发现调节性T细胞(Treg)对gp96免疫功能有显著抑制作用,随着对影响gp96免疫功能的免疫抑制机制的深入了解,以及利用汉逊酵母表达有免疫活性的全长gp96蛋白体系的建立,gp96将在治疗肿瘤及传染性疾病中发挥更大的作用。 Heat-shock protein gp96 associates with antigenic peptides derived from tumor and virus.Exogenous gp96-peptide complexes are taken up by antigen-presenting cells through interaction with its receptor CD91 on the cell surface,and cross-present antigenic peptides to MHC class I molecules by a peptide relay line in the endoplasmic reticulum for specific T-cell activation.Meanwhile,gp96 has been shown to initiate innate immune responses through interaction with toll-like receptor 2 and toll-like receptor 4.Recent studies have shown a gp96-mediated immune balance between CTL and Tregs.With the further understanding of counteracting immunosuppressive mechanisms in gp96-induced cellular immune responses,and establishment of high level production of recombinant gp96 by the yeast,gp96 appears to be a promising candidate for designing effective therapeutic vaccines against tumor and infectious diseases.
出处 《生物工程学报》 CAS CSCD 北大核心 2012年第3期261-266,共6页 Chinese Journal of Biotechnology
基金 国家自然科学基金(Nos.30970146 91029724 81021003)资助~~
关键词 GP96 T细胞 调节性T细胞 肿瘤 传染病 gp96 T cell regulatory T cell(Treg) tumor infectious diseases
  • 相关文献

参考文献7

  • 1Linderoth NA,Popowicz A,Sastry S.Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96(Grp94).J Biol Chem,2000,275(8):5472-5477.
  • 2SenGupta D,Norris PJ,Suscovich TJ,et al.Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.J Immunol,2004,173(3):1987-1993.
  • 3Robert J,Ramanayake T,Maniero GD,et al.Phylogenetic conservation of glycoprotein96 ability to interact with CD91and facilitate antigen cross-presentation.J Immunol,2008,180(5):3176-3182.
  • 4Kropp LE,Garg M,Binder RJ.Ovalbumin-derived precursor peptides are transferred sequentially from gp96and calreticulin to MHC class I in the endoplasmic reticulum.J Immunol,2010,184(10):5619-5627.
  • 5Randow F,Seed B.Endoplasmic reticulum chaperone gp96is required for innate immunity but not cell viability.Nat Cell Biol,2001,3(10):891-896.
  • 6孟颂东,高福,田波.热休克蛋白-多肽复合物在肿瘤和传染性疾病免疫中的作用[J].生物工程学报,2000,16(4):425-428. 被引量:16
  • 7王彦中,王赛锋,张小俊,李杨,赵世宇,孟颂东.热休克蛋白HSP70和gp96增强乙肝DNA疫苗的细胞和体液免疫应答[J].生物工程学报,2011,27(5):790-798. 被引量:8

二级参考文献24

  • 1闻玉梅.治疗性疫苗的研究进展[J].中华微生物学和免疫学杂志,1996,16(3):155-158. 被引量:24
  • 2Meng SD, Gao T, Gao GF, et al. HBV-specific peptide associated with heat shock protein gp96. Lancet, 2001, 357(9255): 528-529.
  • 3Liu Z, Li XH, Qiu LP, et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J lmmunol, 2009, 39(11): 3110-3120.
  • 4Yan JB, Liu XQ, Wang Y, et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med, 2007, 9(2): 107-121.
  • 5Aguilar JC, Lobaina Y, Muzio V, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Thl response against hepatitis B surface antigen. Immunol Cell Biol, 2004, 82(5): 539-546.
  • 6Betancourt AA, Delgado CA, Estevez ZC, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis, 2007, 11(5): 394 401.
  • 7Pakravan N, Soleimanjahi H, Hassan ZM. GP96 C-terminal improves Her2/neu DNA vaccine. J Gene Med, 2010, 12(4): 345-353.
  • 8Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol, 2010, 58(4): 288-295.
  • 9Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 2009, 137(5): 1593 -1608.
  • 10Zheng YL, Zhao LS, Zhou TX, et al. Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. Virol J, 2009, 6: 99.

共引文献22

同被引文献39

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部